The trademark application TMALIN was filed by MediLink Therapeutics(Suzhou)Co.,Ltd., a corporation established under the laws of the People's Republic of China (the "Applicant"). The application was published for oppositions on June 12, 2022, and still open for oppositions.
The application was filed in English (Spanish was selected as the second language).